Background. Twenty-five percent of medullary thyroid cancer (MTC) cases are hereditary. The ideal age for prophylactic thyroidectomy is based on the specific RET mutation involved. The purpose of this study was to determine whether such age-appropriate prophylactic thyroidectomy results in improved disease-free survival. Methods. Twenty-eight patients underwent thyroidectomy for hereditary MTC at our institution. Age-appropriate thyroidectomy was defined according to the North American Neuroendocrine Tumor Society (NANETS) guidelines. Patients who had age-appropriate surgery (group 1, n = 9) were compared to those who had thyroidectomy past the recommended age (group 2, n = 19). Results. The mean age was 13 ± 2 years, and 61 % were
female. Patients in group 1 were younger than in group 2 (4 ± 1 vs. 17 ± 2 years, p \ 0.01). There were no significant differences in gender or RET mutation types between these two groups. Group 1 patients were cured with no disease recurrence compared with group 2 patients who had a 42 % recurrence rate (p = 0.05). Subanalysis of group 2 identified that patients who underwent surgery without evidence of disease did so at a shorter period following the guidelines compared with those who underwent therapeutic surgery (2 ± 2 vs. 16 ± 2 years, p = 0.01) and had longer disease-free survival (100 vs. 27 %, p = 0.005). Conclusions. Patients with hereditary MTC should undergo age-appropriate thyroidectomy based on RET mutational status to avoid recurrence. Patients who are past the recommended age should have surgery as early as possible to improve disease-free survival.
Medullary thyroid cancer (MTC) is a neuroendocrine malignancy of the thyroid C cells (parafollicular cells).
MTC has a varied presentation from tumors that remain stable for many years to highly malignant tumors. 1 Currently MTC accounts for 3 % of all thyroid cancers but is responsible for 14 % of all thyroid cancer-related deaths. 2, 3 MTC may occur sporadically or may be inherited. Sporadic MTC accounts for 75 % of all cases. 4, 5 Hereditary MTC is caused by a single germline mutation in the rearranged during transfection (RET) protooncogene. In 1991, the RET gene was found to be located on chromosome 10q11.2 where it encodes a transmembrane tyrosine receptor. 6 In 1993, it was first discovered that mutations in RET were associated with MEN and MTC. 7 Whereas sporadic MTC usually presents as a unifocal clonal population of tumor cells, hereditary MTC is typically multifocal and bilateral. Also, hereditary MTC has an earlier age of onset and usually a more aggressive course. 8 Hereditary MTC may occur in association with other neuroendocrinopathies in the setting of multiple endocrine neoplasia type 2 (MEN 2A or 2B) or alone as familial MTC (FMTC). 9 In the setting of hereditary MTC, disease prognosis is dependent on the specific RET mutation involved. 1, 10 The North American Neuroendocrine Tumor Society (NANETS) has classified RET mutations into three risk levels, based on the age-associated risk of development of MTC. For all forms of hereditary MTC, prophylactic total thyroidectomy is recommended. 2 Although the practice of prophylactic thyroidectomy begun in the 1990s, the risk of disease recurrence is still not well defined. 2 Although previous studies have reported positive outcomes for those undergoing prophylactic surgery at a young age, the prognosis of those having surgery past the recommended age is not well characterized. 11 Furthermore, the relationship between the amount of time waited past guidelines and the risk of developing disease also is indeterminate.
The purpose of the present study was to determine whether age-appropriate thyroidectomy improves disease free-survival compared with having surgery past the recommended age. The time past the guidelines of the thyroidectomy performed was correlated to disease status at surgery and disease recurrence following surgery.
METHODS
A review of a prospective database was performed of all patients undergoing thyroidectomy or neck dissection from 1994 to 2010 using the University of Wisconsin Thyroid Surgery Database. All patients with a preoperative or postoperative diagnosis of MTC as well as those who tested positive for RET mutations were identified in the database. Those who tested positive for RET mutations or those with three or more family members diagnosed with MTC were classified as hereditary MTC patients. The remaining patients were classified as sporadic MTC patients and were excluded.
The 28 hereditary MTC patients were subdivided into two groups: group 1: those having age-appropriate thyroidectomy; and group 2: those having surgery past the recommended age. Age-appropriate surgery was defined by the NANETS guidelines, which recommend surgery before age 10 years for level 1 mutations, before age 5 years for level 2 mutations, and before age 6 months for level 3 mutations. These are identical to the ATA guidelines, which existed during the period of study. Data for these two groups were then collected, including demographics, mutation level, preoperative and postoperative diagnosis, disease recurrence status, and time of last follow-up.
A subanalysis of group 2 was performed. This group was divided into group 2a: those patients having no radiographic or clinical evidence of MTC at surgery (prophylactic thyroidectomy) (ATA) and group 2b: those were having a diagnosis of MTC at surgery (therapeutic thyroidectomy). These two subgroups were compared based on disease recurrence and how long past the NANETS recommended age each group waited to have their thyroidectomy ( Fig. 1) .
To identify differences between group 1 and group 2 and between groups 2a and 2b, univariate statistical analysis was performed using the Fisher's exact test and t test. Also, a survival analysis between groups 1 and 2 and between groups 2a and 2b was performed using Kaplan-Meier analysis. All statistical calculations were completed using statistical software SPSS version 17 (SPSS Inc., Chicago, IL). A p value of B0.05 was considered to represent statistical significance for all comparisons.
RESULTS
Forty-one patients underwent prophylactic or therapeutic total thyroidectomy for MTC from 1994 to 2010 at the University of Wisconsin. Twenty-eight cases were classified as hereditary MTC, whereas 13 cases were sporadic MTC. Of the hereditary MTC cases, 9 (32 %) patients had ageappropriate surgery (group 1), whereas 19 (68 %) patients had surgery past the recommended age (group 2; Fig. 1 ).
Of the 28 hereditary MTC patients, 61 % were female and the mean patient age at the time of surgery was 13 ± 2 years. Twenty-four patients were diagnosed with MEN type 2A, one patient with MEN type 2B, and three with familial MTC. Serum calcitonin level was not detectable in any of the patients who underwent a prophylactic surgery, but the mean level was 380.3 ± 144 pg/ml in patients who underwent therapeutic surgery (Tables 1, 2) .
Patients in group 1 and group 2 had an average followup time of 5.1 ± 1.8 and 11.2 ± 1.9 years following thyroidectomy. At the most recent follow-up, all nine patients in group 1 had no evidence of MTC. However, eight (42 %) patients in group 2 had recurrent MTC, which required one or more additional surgical interventions. Kaplan-Meier survival analysis indicated that those in group 1 had an improved disease-free survival compared with those in group 2 (p = 0.05; Fig. 2) .
Of the 19 patients in group 2 who had their surgery past the recommended age, 8 (42 %) patients (group 2a) still underwent a prophylactic thyroidectomy. The remaining 11 (58 %) patients (group 2b) had therapeutic thyroidectomy due to a diagnosis of MTC at the time of surgery. One patient from group 2b had left neck lymph nodes metastasis at initial presentation. Patients in group 2a were significantly younger than those in group 2b (12 ± 3 vs. 21 ± 2 years, p = 0.04). Those in group 2a underwent thyroidectomy a median time of 2 ± 2 years past the NANETS recommended age, whereas those in group 2b were 16 ± 2 years past the guidelines (p = 0.01). All group 2a patients had no recurrence of MTC; however, 8 of 11 patients in group 2b (73 %) had recurrent disease that required reoperation (p = 0.005; Fig 3) .
DISCUSSION
In our patient population, it is evident that age-appropriate thyroidectomy, based on RET mutation status, prolongs disease-free survival in the setting of hereditary MTC. In the nine patients who underwent age-appropriate thyroidectomy, 100 % remained disease-free at their latest follow-up. An awareness of a family history of MTC allowed for early genetic screening to identify these RET carriers and prompt surgical intervention. This finding underscores the continued importance of early genetic screening when a family history of MTC or MEN syndrome exists.
Unfortunately, many patients harboring RET mutations present for thyroidectomy past the recommended age. In these cases, the disease-free survival time following surgery is highly variable. [11] [12] [13] In the 19 patients who had surgery past the guideline age, 42 % had noted recurrent MTC following thyroidectomy. This represents a significant decrease in disease-free survival compared with patients who have age-appropriate surgery. The reason that RET carriers often are unidentified until after they present with disease remains unclear. It is possible that this is the result of a patient's lack of awareness of any family history of MTC. Also, some insurance companies do not routinely pay for RET mutation testing. This is an expensive test that many patients may be unable to afford. This factor may contribute to a lack of comprehensive family screening for MTC in some cases. Lastly, it is possible that patients who are seen by an endocrinologist or had been operated on by endocrine-trained surgeons are more likely to be identified as a potential RET carrier and undergo screening. However, many patients are from rural areas that do not have local expertise in the disease and are not screened or referred. Whereas having age-appropriate surgery is ideal, the chance for surgical cure of MTC remains high if the patient presents only shortly after the guideline age. 11 Of the 19 patients who had surgery past the recommended age, the 8 patients who still had a prophylactic surgery had no disease recurrence following surgery. However, 11 had therapeutic surgery, with a high rate (73 %) of disease recurrence following surgery. The largest identifiable difference between these two groups was the time length that had passed between the guideline age and the actual age for surgery. This finding emphasizes that if a patient is to present beyond the guideline age, they should still be advised to undergo thyroidectomy immediately. If surgery can be performed only a few years past the guideline time, the patient may possibly still have prophylactic surgery without evidence of MTC and this will result in significantly improved disease-free survival. However, the longer the patient waits beyond the guideline age, the greater their risk of developing disease before surgery and having disease recurrence following surgery.
The findings of our study are consistent with previous studies. Skinner et al. 11 found that MEN-2A patients who had surgery before age 8 years had lower rates of persistent or recurrent disease than older patients. Also in their series, 33 of 50 patients had developed MTC by the time of surgery, 6 of whom developed recurrent disease following surgery; all 6 of these patients had surgery several years beyond the recommended age. Indeed, O'Riordain et al. 12 also found a strong correlation between age at surgery and rate of disease recurrence following surgery. In a nationwide study in the Netherlands, Schreinemakers et al. 13 reported a 34 % disease-recurrence rate among those who had surgery past the recommended age versus 0 % recurrence in those who underwent age-appropriate surgery. The findings of these studies strongly concur with the findings of our study; it appears that the most important prognostic factor for disease-free survival in hereditary MTC is age at surgery. This association is believed to be due to the observation that disease advancement from C-cell hyperplasia to MTC is age-related. 14, 15 As patients progress in age, there is a greater risk of MTC development with local or distant metastases, making surgical cure highly improbable. 14 The ATA guidelines state that infants with MEN 2B should undergo prophylactic total thyroidectomy as soon as possible, ideally within the first year of life at an experienced tertiary care setting. It also is recommended that children with codon 634 mutations undergo prophylactic total thyroidectomy before they are 5 years old at an experienced tertiary care center. In addition, prophylactic total thyroidectomy may be delayed beyond age 5 years for RET carriers in the setting of a normal annual basal stimulated serum calcitonin, normal annual neck ultrasound, less aggressive MTC family history, and family preference. Surgery is indicated if all of these features are not present. For higher risk mutations, treatment should be considered before age 5 years in an experienced tertiary care setting, regardless of other factors. 16 The main limitation of our study is the length of followup. The patients in group 1 were followed for a significantly shorter period of time than the patients in group 2 (5 vs. 11 years). Therefore, to ensure that those undergoing prophylactic surgery remain disease-free in the future, a longer-term study is needed. Also, although 28 patients were included, a larger patient population may be needed to further validate the observed trends and to increase the power of the study. Lastly, this is a retrospective study that is prone to selection bias due to inclusion of patients who had surgery. A prospective study is unlikely to be performed due to the rarity of the disease.
CONCLUSIONS
Prophylactic thyroidectomy for patients with hereditary MTC is a key for disease management. Following the NANETS age-appropriate thyroidectomy guidelines based on RET mutational status is recommended. Patients who have surgery after the recommended age should have surgery as early as possible, before disease development, to improve disease-free survival.
